Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting

Nonunion Fracture Clinical Trial

Official title:

Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting. A Randomized, Double-blind, Controlled Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01429012
• Other study ID #: TJT1101
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 2012
• Est. completion date: November 2016

Study information

• Verified date: May 2021
• Source: University of Liege
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Bone fractures heal most of the time particularly well and without complications. The solidification takes rarely more than two to three months. The wound healing depends greatly on a good blood supply and needs several steps. These processes culminate in a new mass of heterogeneous tissue which is known as the fracture callus. Unfortunately, 2%-5% bone fractures cannot achieve a proper solidification and between the ununited fragments a scar tissue appears. This incorrect healing induces pain and even infections. When this situation persists more than 6 months, it is referred to as nonunion fracture, which will require some form of intervention to stimulate the natural healing process of the body. First of all, good surgical techniques with stable immobilization should be applied and local infection should be excluded. Then stimulation of the callus is required. Cell therapy with bone marrow cells has emerged as a promising new approach for bone regeneration. Animal studies as well as preliminary human studies have shown that Mesenchymal Stem Cells, a particular kind of stem cells isolated from the bone marrow, could induce callus formation when injected in the nonunion site of a broken bone.

In this study the investigators aim at determining whether Mesenchymal Stem Cells (MSC) isolated from the patient's bone marrow and injected in the nonunion site could be a safe and effective treatment for nonunion fractures. Patients will be randomized in two groups; one injected with Mesenchymal Stem Cell and the other injected with placebo. The investigators seek also to know how long it takes to develop the callus formation and whether there is a partial or a complete callus formation.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female; female patients must use a reliable contraception method

• Age = 18 years

• Fracture having no radiological callus after 6 months and absence of any hypertrophic bone reaction.

• No sepsis

• Good skin covering

• Be able and willing to participate in the study

• Written informed consent

Exclusion Criteria:

• Evidence of malignancy (except non-melanoma skin cancer) in the past five years

• Pregnancy or breastfeeding

• Patient positive by serology or PCR for HIV, hepatitis B or C infection

• Insufficient reduction of the fracture with displaced fragments

• Evidence of local sepsis by clinical signs, biological parameters (CRP) and/or positive isotopic scan using Indium-labelled leucocytes

Related Conditions & MeSH terms

• Atrophy
• Fractures, Bone
• Fractures, Ununited
• Nonunion Fracture

Intervention

Biological:
• Mesenchymal Stem Cells
Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.

Other:
• Culture medium without MSC.
2 ml of culture medium.

Locations

Country	Name	City	State
Belgium	Liège University Hospital	Liège

Sponsors (1)

Lead Sponsor	Collaborator
University of Liege

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of Mesenchymal Stem Cells injection in nonunion fractures.	Follow-up for revealing any significant immediate or late adverse effects.	12 months
Primary	Proportion of patients receiving Mesenchymal Stem Cells that develop a partial or complete callus at 6 and 12 months, compared to patients receiving placebo.	Radiological evaluation of the callus by standard X-rays and computed tomography (CT).	6 and 12 months
Secondary	Proportion of patients receiving Mensechymal Stem Cells that develop a partial or complete callus at 2, 3, 4, 8 and 10 months, compared to patients receiving placebo	Radiological evaluation of the callus by standard X-rays and computed tomography (CT).	2, 3, 4, 8 and 10 months
Secondary	Timing of development of a partial or complete callus in the 2 groups.	Time necessary for a partial or a complete callus formation. Radiological evaluation of the callus by standard X-rays and computed tomography (CT).	12 months for one injection or 18 months when a second injection is needed
Secondary	Patient evaluation of pain and global satisfaction.	This evaluation will be measured through a 100-mm Visual Analogue Scale at 2, 3, 4, 6, 8, 10 and 12 months in the 2 groups.	12 months
Secondary	Proportion of patients achieving different degrees of functional success.	The functional assessment will be evaluated in Mesenchymal Stem Cells treated and untreated patients by an orthopaedic surgeon and will include a 4-points scale: 0 = only passive motion allowed; 1 = only active mobilization without any opposition allowed; 2 = active mobilization with some opposition and partial weight-bearing allowed; 3 = weight-bearing and full active mobilization allowed	2, 3, 4, 6, 8, 10 and 12 months
Secondary	Incidence of adverse events and severe adverse events in the 2 groups.	Adverse events and serious adverse events will be continuously monitored .	12 months for one injection and 18 months when a second injection is performed
Secondary	Evaluation of early homing of Mesenchymal Stem Cells.	Indium radiolabeled Mesenchymal Stem Cells (MSC) will be visualized with a Siemens e-CAM dual head gamma camera: 10% of the total amount of MSC will be incubated with 200 µCi In-111-oxine. The radiolabelled cells will be mixed with the unlabelled ones. Twenty-four hours after injecting the cells into the target bone lesion, static images centered over the injection site and whole-body images will be acquired during 20 minutes. This will be performed with a Siemens e-CAM dual head gamma camera.	24 hours
Secondary	Value of [18F]-NaF PET scans for early prediction of the onset of the bone healing process.	PET Fluor kinetics could identify early and perhaps quantify the increase of bone forming in the treated area. Four [18F]-NaF PET scan studies will be performed: at baseline, as well as around days 7-9 (1 week), 27-33 (one month) and 83-97 (three months).	3 months